The product:
Concept and Technology

Surgery is the standard of care for resectable solid tumors.
Loco-regional approaches, in combination with chemotherapy and/or radiotherapy, are standard therapy in the following settings:

  • neo-adjuvant: before treatment, to reduce tumoral masses or
  • adjuvant: post treatment, to reduce risk of recurrence

In the presence of a combination of systemic chemotherapy, radiotherapy is the standard approach, whereby radiotherapy can trigger an anti-cancer immune response that can be further exploited by the new immune-stimulator drugs.

Controlled administration of radionuclides falls in the field of loco-regional therapies for the treatment of tumors. Administration of β-emitting radionuclides vs external radiotherapy presents several advantages: high radiation dose delivery (improved efficacy), low surrounding tissue penetration, low impact on blood vessels, high control of administered energy (limited side effects).

Radiation therapy based on β-emitting microspheres is currently approved in clinical practice only for intra-arterial administration in hepatic tumors (with proven safety and efficacy); multiple work-up procedures are needed to avoid unwanted diffusion of radionuclides in the adjacent organs.

Radionuclides are administered through a delivery system device engineered to guarantee a precise delivery of the required dose of radiation where it is needed, thus overcoming some disadvantages of first line treatment options.

Additional applications for other loco-regional treatments are being researched.

Contact us

    Technologies SpA

    Legal headquarters:

    Piazzetta Umberto Giordano, 4
    20122 Milano, Italy

    VAT number: 06496571214

    REA MI-2502397

    Paid-in capital: € 784.616

    © BetaGlue 2022. All rights reserved.